IRIS
RIA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.560
EU - Europa 2.324
AS - Asia 1.389
SA - Sud America 11
AF - Africa 5
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.546
CN - Cina 837
SE - Svezia 768
IT - Italia 405
SG - Singapore 388
DE - Germania 305
UA - Ucraina 253
FI - Finlandia 194
GB - Regno Unito 172
FR - Francia 65
BE - Belgio 53
IN - India 52
IE - Irlanda 40
VN - Vietnam 40
CZ - Repubblica Ceca 28
HK - Hong Kong 26
JP - Giappone 19
CA - Canada 14
NL - Olanda 9
BR - Brasile 8
PL - Polonia 8
IR - Iran 7
RU - Federazione Russa 7
LT - Lituania 5
EG - Egitto 4
KR - Corea 4
AU - Australia 3
ES - Italia 3
TR - Turchia 3
TW - Taiwan 3
CH - Svizzera 2
CL - Cile 2
EU - Europa 2
HU - Ungheria 2
IQ - Iraq 2
MK - Macedonia 2
TH - Thailandia 2
AR - Argentina 1
AZ - Azerbaigian 1
ID - Indonesia 1
IL - Israele 1
LB - Libano 1
MW - Malawi 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
Totale 14.295
Salva come PNG Salva come JPEG
Città #
Fairfield 1.541
Chandler 1.133
Woodbridge 1.070
Ashburn 770
Houston 659
Seattle 632
Nyköping 592
Jacksonville 581
Cambridge 561
Wilmington 505
Ann Arbor 482
Singapore 293
Lawrence 213
Roxbury 212
New York 209
Nanjing 203
Beijing 159
Bari 144
Des Moines 133
Inglewood 111
Princeton 105
Boardman 89
San Diego 62
Nanchang 57
Brussels 53
Shenyang 52
Helsinki 51
Los Angeles 45
Brooklyn 42
Dearborn 42
Dong Ket 40
Munich 40
Dublin 38
Jiaxing 38
London 36
Rome 32
Hebei 31
Brno 27
Leawood 27
Pune 26
Santa Clara 25
Tianjin 25
Marseille 24
Washington 23
Guangzhou 22
Grafing 20
Changsha 18
Osaka 16
Paris 16
Augusta 15
Redwood City 15
Jinan 14
Kunming 14
Zhengzhou 14
Falls Church 12
Florence 11
Milan 9
Toronto 9
San Mateo 8
Shanghai 8
Taizhou 8
Kilburn 7
Monmouth Junction 7
Ningbo 7
Wuhan 7
Wuxi 7
Ardabil 6
Brescia 6
Hefei 6
Islington 6
Mumbai 6
Tappahannock 6
Norwalk 5
Nürnberg 5
Prescot 5
Acton 4
Alcamo 4
Aragona 4
Auburn Hills 4
Bengaluru 4
Chicago 4
Chiswick 4
Frankfurt am Main 4
Fuzhou 4
Hong Kong 4
Hounslow 4
Messina 4
New Bedfont 4
Palermo 4
Parma 4
Radomsko 4
Shenzhen 4
Verona 4
Amsterdam 3
Cutrofiano 3
Detroit 3
Istanbul 3
Jinhua 3
New Delhi 3
Obrigheim 3
Totale 11.641
Salva come PNG Salva come JPEG
Nome #
Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival 228
Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease. 147
Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients 133
Extramedullary Plasmacytoma Mimicking Pancreatic Cancer: An Unusual Presentation 128
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 123
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 122
Involvement of NOTCH signaling in multiple myeloma angiogenesis and progression 116
Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients 116
Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma 115
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies 113
Evidence for bone marrow adult stem cell plasticity: Properties, molecular mechanisms, negative aspects, and clinical applications of hematopoietic and mesenchymal stem cells transdifferentiation 111
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neo-angiogenic biomarkers 111
Identify multiple myeloma stem cells: Utopia? 110
Multiple myeloma macrophages: Pivotal players in the tumor microenvironment 110
Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass 109
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing 108
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment 108
Functional and biological role of endothelial precursor cells in tumour progression: A new potential therapeutic target in haematological malignancies 107
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma 106
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 106
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 105
Neutropenia and G-CSF in lymphoproliferative diseases 103
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis 102
Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea 101
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma 101
null 101
Delayed complete remission in a patient with multiple myeloma 99
Fibrinogen apheresis in the treatment of peripheral arterial disease 98
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 98
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. 97
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target? 97
Vascular Endothelial Growth Factor and its Receptors in Multiple Myeloma 95
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 95
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 94
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 94
Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes Bortezomid resistance in multiple myeloma patients. 94
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts 93
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma 93
Does a reduction of adhesion molecules by LDL-apheresis have a role in the treatment of sudden hearing loss? 91
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials 90
Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma 89
Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers? 89
Angiogenesis in multiple myeloma 89
Circulating miRNA markers show promise as new prognosticators for multiple myeloma 89
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 88
null 88
Could multiple myeloma VEGF modify the systemic microcirculation? 88
Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression 88
null 87
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: In vitro and in vivo studies 86
Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells 85
A multiple myeloma that progressed as type i cryoglobulinemia with skin ulcers and foot necrosis: A case report 85
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 83
Endothelial cells in the bone marrow of patients with multiple myeloma 82
Efficacy and safety of once weekly bortezomib in multiple myeloma patients 82
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 82
An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis 81
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma 80
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 80
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients 79
Circulating cell adhesion molecules are increased in hypertensive left ventricular hypertrophy 78
TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically 77
null 76
Angiogenesis and progression in human melanoma 76
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone(VMP) in untreated multiple myeloma patients with renal impairment. 76
Cross-talk between hematopoiesis and angiogenesis signaling pathways 76
High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma 76
Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture 75
null 75
Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas 75
In vivo time-course of the angiogenic response induced by multiple myeloma plasma cells in the chick embryo chorioallantoic membrane 75
Effect of low-density lipoprotein apheresis on circulating endothelial progenitor cells in familial hypercholesterolemia 74
Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases 74
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients 74
Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis 74
Monoclonal gammopathy as a marker of primary cerebral lymphoma 73
Bone marrow dendritic cells induce myeloma cell resistance to CD8+ T cell-mediated killing 73
High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma 73
Bortezomib treatment modulates autophagy in multiple myeloma 73
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma 72
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype 72
null 71
A weekly infusion of bortezomib reduces peripheral neuropathy 71
A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents 71
Angiogenesi e progressione tumorale nel melanoma 70
Mast cell contribution to angiogenesis related to tumour progression 70
Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane 70
Cancer-related coagulopathy (Trousseau's syndrome): Review of the literature and experience of a single center of internal medicine 70
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 70
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 70
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 70
Effects of severe hypertension on soluble cellular adhesion molecule levels 69
Angiogenesi midollare e molecole di adesione per l’endotelio nei pazienti con mieloma multiplo (MM) e con gammapatia monoclonale non mielomatosa (MGUS) 69
Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women 69
Role of angiogenesis and microenvironment in melanoma progression 69
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 69
Role of stromal cells in neovascularization of multiple myeloma 68
Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma 68
null 67
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression 67
Totale 8.953
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.533
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.409 0 0 0 0 360 252 369 352 478 200 272 126
2020/20212.575 175 157 183 151 370 190 205 200 182 335 254 173
2021/20221.639 153 203 17 52 63 106 92 84 95 122 272 380
2022/20232.864 379 296 183 278 328 419 21 303 526 22 53 56
2023/20241.171 99 196 71 60 104 322 60 70 7 22 30 130
2024/2025866 126 96 322 204 118 0 0 0 0 0 0 0
Totale 14.903